Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Immunotoxins: experimental design

  • 1 and
  • 2
Breast Cancer Research20013 (Suppl 1) :A18

https://doi.org/10.1186/bcr342

  • Received: 10 May 2001
  • Published:

Keywords

  • Tumor Cell
  • Clinical Study
  • Cancer Research
  • Animal Experiment
  • Significant Activity

One of the major goals of tumor immunotherapy is to overcome immune escape and tumor anergy mechanisms. The identification of (relatively) tumor-specific epitopes is more important for adoptive immunotherapy strategies than their immunogenicity. In the immunocellular approach, D44v-epitope-specific T-cells were cloned introducing a fusion gene encoding the single chain Fv-fragment of CD44v-specific mAb and the zeta-chain of the TCR complex. MHC-independent retargeted cytotoxicity could be shown toward antigen-expressing tumor cells in vitro and in vivo. In a humoral approach, the fusion gene for a Her2neu-specific scFv and a bacterial toxin was expressed in E coli. After purification the fusion toxin showed significant activity in animal experiments using Her2-neu-expressing tumors. Meanwhile, the first six patients suffering from Her2-neu-expressing cancers have been treated topically so far. No significant systemic or local side effects could be detected. Four out of six patients had a local PR/CR. Further clinical studies are warranted and ongoing.

Authors’ Affiliations

(1)
Department of Obstetrics & Gynecology, Düsseldorf University Medical Center, Düsseldorf, Germany
(2)
Georg-Speyer-Haus (Chemotherapeutical Research Institute), Frankfurt, Germany

Copyright

© BioMed Central Ltd 2001

Advertisement